Evidence map›Paper›PMID 41913008›Full record

SynthesisAnnals of surgical oncology2026

Efficacy and Safety of Tranexamic Acid in Solid Cancer Surgeries: A Systematic Review and Meta-analysis of Randomized Controlled Trials with GRADE Assessment.

Asmaa Soliman, Ahmed Adel Abdel Azim, Abdullrahman Elgarawany, Ahmed S A Osman, Ahmed Rezk, Sally Muhamed Seliem, Elsayed S Moubarak, Suliman Hassan Abdalaziz, Israa Ahmed Qutob

Abstract readSystematic ReviewMeta-AnalysisReview
PubMed Publisher
In one paragraph

Synthesis in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Asmaa Soliman *Faculty of Medicine, Zagazig University, Sharqia, Egypt. asmaamohamed8967@gmail.com.
Ahmed Adel Abdel Azim *Faculty of Medicine, Assiut University, Assiut, Egypt.
Abdullrahman Elgarawany *Faculty of Medicine, Galala University, Galala City, Suez, Egypt.
Ahmed S A Osman *Faculty of Medicine, Minia University, Minia, Egypt.
Ahmed RezkAl-Azhar University Hospital, Damietta, Egypt.
Sally Muhamed SeliemFaculty of Medicine, Mansoura University, Mansoura, Egypt.
Elsayed S MoubarakFaculty of Medicine, Cairo University, Cairo, Egypt.
Suliman Hassan AbdalazizFaculty of Medicine, Ain Shams University, Cairo, Egypt.
Israa Ahmed QutobFaculty of Medicine, Alexandria University, Alexandria, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is a significant risk of blood loss and transfusion requirements during surgeries for different cancers, raising perioperative morbidity and mortality. The antifibrinolytic drug tranexamic acid (TXA) has been studied to address this issue, but the results remain conflicting. This systematic review and meta-analysis pools all available evidence regarding the use of this medication in cancer surgeries. PATIENTS AND

methodsThe PubMed, Scopus, Web of Science, and Cochrane CENTRAL databases were used for data retrieval until 29 April 2025. Any randomized controlled trial involving surgical patients with cancer who received TXA as the intervention was included. The main addressed outcomes were perioperative blood loss, transfusion requirements, and complications. Study quality and evidence certainty were appraised with the Cochrane RoB 2.0 tool and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework.

resultsA total of 16 RCTs with 1830 patients were analyzed. TXA markedly reduced total, intraoperative, and postoperative blood loss compared with control. Hemoglobin changes were also smaller in the TXA group. Intraoperative blood component and perioperative red blood cell transfusions were lower with TXA. TXA was also linked to a modest reduction in operative time. No significant differences were observed between the groups for perioperative complications, reoperation rate, in-hospital or 30-day mortality, and length of hospital stay. GRADE assessments for the outcomes were mainly moderate or low, except for two that had very low certainty.

conclusionsTXA appears to statistically improve perioperative outcomes in cancer surgeries while maintaining a favorable safety profile.

Indexed as

Antifibrinolytic AgentsBlood Loss, SurgicalNeoplasmsTranexamic AcidBlood TransfusionHumansRandomized Controlled Trials as TopicAntifibrinolytic AgentsTranexamic AcidBlood lossBlood transfusion ratesCancer surgeriesMorbidityMortalityTranexamic acid

Identifiers

PMID41913008

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.